$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000173728724000073 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$16.33M
YoY Change		-4.15%
% of Gross Profit
Research & Development		$44.71M
YoY Change		-2.75%
% of Gross Profit
Depreciation & Amortization		$3.207M
YoY Change		-10.17%
% of Gross Profit
Operating Expenses		$71.77M
YoY Change		13.89%
Operating Profit		-$71.77M
YoY Change		13.97%
Interest Expense		$5.481M
YoY Change		-11.74%
% of Operating Profit
Other Income/Expense, Net		$5.481M
YoY Change		230.18%
Pretax Income		-$66.29M
YoY Change		8.11%
Income Tax
% Of Pretax Income
Net Earnings		-$66.29M
YoY Change		8.12%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.32
Diluted Earnings Per Share		-$0.32
COMMON SHARES
Basic Shares Outstanding	209.7M shares	209.1M shares
Diluted Shares Outstanding		209.2M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$291.6M
YoY Change		-37.37%
Cash & Equivalents		$51.24M
Short-Term Investments		$240.3M
Other Short-Term Assets		$12.85M
YoY Change		62.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$304.4M
YoY Change		-35.7%
LONG-TERM ASSETS
Property, Plant & Equipment		$88.99M
YoY Change		-13.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$111.8M
YoY Change		198.19%
Other Assets		$4.970M
YoY Change		-48.1%
Total Long-Term Assets		$284.7M
YoY Change		19.19%
TOTAL ASSETS
Total Short-Term Assets		$304.4M
Total Long-Term Assets		$284.7M
Total Assets		$589.1M
YoY Change		-17.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$5.506M
YoY Change		-11.27%
Accrued Expenses		$27.07M
YoY Change		-13.25%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$32.57M
YoY Change		-13.46%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$7.666M
YoY Change		415.88%
Total Long-Term Liabilities		$7.666M
YoY Change		415.88%
TOTAL LIABILITIES
Total Short-Term Liabilities		$32.57M
Total Long-Term Liabilities		$7.666M
Total Liabilities		$125.4M
YoY Change		-2.98%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.760B
YoY Change		17.33%
Common Stock		$2.223B
YoY Change		7.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$463.7M
YoY Change
Total Liabilities & Shareholders Equity		$589.1M
YoY Change		-17.3%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$66.29M
YoY Change		8.12%
Depreciation, Depletion And Amortization		$3.207M
YoY Change		-10.17%
Cash From Operating Activities		-$44.12M
YoY Change		-20.56%
INVESTING ACTIVITIES
Capital Expenditures		$429.0K
YoY Change		2045.0%
Acquisitions
YoY Change
Other Investing Activities		-$75.56M
YoY Change		120.56%
Cash From Investing Activities		-$75.99M
YoY Change		121.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		679.0K
YoY Change		-84.14%
NET CHANGE
Cash From Operating Activities		-44.12M
Cash From Investing Activities		-75.99M
Cash From Financing Activities		679.0K
Net Change In Cash		-119.4M
YoY Change		39.65%
FREE CASH FLOW
Cash From Operating Activities		-$44.12M
Capital Expenditures		$429.0K
Free Cash Flow		-$44.54M
YoY Change		-19.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	457-2700
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	ALLO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168642238	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168642238	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	210000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2075252000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83155000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	365542000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12851000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10418000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	304415000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	459115000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	111821000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46313000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63703000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88989000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99478000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	32571000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37079000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	85135000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88346000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7666000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5179000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	125372000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	157000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-955000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	463748000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	512233000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44713000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45977000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	147327000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	188253000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16333000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17041000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	49687000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54449000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	209672091	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	209500137	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	209500137	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	169000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2223265000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1759884000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1562233000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	589120000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	642837000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	130604000	usd
CY2023Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	71774000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	63018000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-71774000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-62996000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20240930#AccruedAndOtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20240930#AccruedAndOtherLiabilitiesCurrent
	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51239000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	240325000	usd
CY2024Q3	us-gaap	Escrow Deposit EscrowDeposit	22320000	usd
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit	0	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4970000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6604000	usd
CY2024Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	0	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3645000	usd
CY2024Q3	us-gaap	Assets Assets	589120000	usd
CY2023Q4	us-gaap	Assets Assets	642837000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5506000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5897000	usd
CY2024Q3	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	27065000	usd
CY2023Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	31182000	usd
CY2024Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	10728000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	15717000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Operating Expenses OperatingExpenses	212731000	usd
	us-gaap	Operating Expenses OperatingExpenses	242702000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-212709000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-242628000	usd
CY2024Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	6705000	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	6205000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	17126000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	12042000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	100000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	100000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1124000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5496000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1968000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10901000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5481000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	709000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15058000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1141000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-66293000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-62287000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-197651000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-241487000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	937000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1440000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1112000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7515000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65356000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60847000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-196539000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-233972000	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	209188551	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	209188551	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	167649010	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	167649010	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	189519897	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	189519897	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153087449	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153087449	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	512233000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	794000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	532000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11924000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	856000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-65000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	28000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	461367000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13559000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-66358000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	147000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	515038000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13387000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	679000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-66293000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	937000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	463748000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	666882000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	603000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18770000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1731000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-99968000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3992000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	592010000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1606000	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	432000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16594000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-79232000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2083000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	621411000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	326000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	432000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15354000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	765000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-62287000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1440000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	580635000	usd
	us-gaap	Profit Loss ProfitLoss	-197651000	usd
	us-gaap	Profit Loss ProfitLoss	-241487000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	38870000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	50718000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10406000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10722000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	6697000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3510000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	15717000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	3000000	usd
	allo	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	4148000	usd
	allo	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	4949000	usd
	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	14000	usd
	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	49000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1688000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7866000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	22320000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2294000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3555000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3591000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	421000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-537000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7200000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4142000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-7109000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4531000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4445000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	164000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-615000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-163602000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-184026000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	437000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1335000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5398000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5623000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	330294000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	461467000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	314501000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	369927000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20754000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	95828000	usd
	allo	Proceeds From Grant Awards ProceedsFromGrantAwards	2280000	usd
	allo	Proceeds From Grant Awards ProceedsFromGrantAwards	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	813000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1932000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1535000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2496000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	110932000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95540000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31916000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7342000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72196000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61531000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79538000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2409000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	allo	Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities	3079000	usd
	allo	Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities	0	usd
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	9308000	usd
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	9013000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The Company is developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. The Company’s engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. The Company believes this key difference will enable it to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2024, the Company entered into (i) an underwriting agreement (Underwriting Agreement) with Goldman Sachs & Co. LLC (Underwriter) and (ii) a Securities Purchase Agreement (Securities Purchase Agreement) with certain members of the Company’s Board of Directors and executive officers or their respective affiliates (Purchasers), pursuant to which the Company sold and issued to the Underwriter and the Purchasers an aggregate of 37,931,035 shares of common stock of the Company at a purchase price of $2.90 per share, in a registered offering transaction (Registered Offering) for aggregate gross proceeds of $110.0 million, before deducting the underwriting discount and commissions and estimated offering expenses payable by the Company. The Registered Offering closed on May 16, 2024. The aggregate fee payable by the Company to the Underwriter was $4.7 million, plus the reimbursement of certain expenses. The Purchasers purchased an aggregate of 1,034,484 shares of common stock of the Company in the Registered Offering.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had cash and cash equivalents and investments of $403.4 million as of September 30, 2024. Since inception through September 30, 2024, the Company has incurred cumulative net losses of $1,759.9 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div>The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	403400000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1759900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, income tax uncertainties, the CIRM award liability and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div>
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	395524000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	617000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000	usd
CY2024Q3	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	396123000	usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	43977000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	240325000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	111821000	usd
CY2024Q3	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	396123000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	444589000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	245000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	756000	usd
CY2023Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	444078000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	78536000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	365542000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2023Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	444078000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P3Y
CY2024Q3	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	1000000.0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	48400000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	2800000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1700000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	148557000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	150562000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	59568000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51084000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88989000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99478000	usd
CY2018Q3	allo	Area Of New Office Building AreaOfNewOfficeBuilding	68000	sqft
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P127M
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2020Q4	us-gaap	Tenant Improvements TenantImprovements	5000000.0	usd
CY2021Q4	allo	Additional Area Of New Office Building AdditionalAreaOfNewOfficeBuilding	47566	sqft
CY2018Q4	allo	Area Of New Office Building AreaOfNewOfficeBuilding	14943	sqft
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P124M
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2018Q4	allo	Tenant Improvement Allowance TenantImprovementAllowance	800000	usd
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	6000000	usd
CY2024Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	6000000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7389000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6775000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	85135000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88346000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	92525000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	95121000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2900000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	3180000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8931000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	9536000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	834000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	587000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2209000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1950000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	3734000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	3767000	usd
	us-gaap	Lease Cost LeaseCost	11140000	usd
	us-gaap	Lease Cost LeaseCost	11486000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	9300000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3197000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12920000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13163000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13612000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	14076000	usd
CY2024Q3	allo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	65386000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	122354000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29829000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	92525000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0625
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M6D
CY2020Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P20Y
CY2020Q3	allo	Lessee Finance Lease Payment Upon Contract Termination LesseeFinanceLeasePaymentUponContractTermination	4300000	usd
CY2024Q3	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	2300000	usd
	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9508639	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	5200000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13400000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38900000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15400000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50700000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38371459	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35507093	shares
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001737287-24-000073-index-headers.html	Edgar Link	pending
0001737287-24-000073-index.html	Edgar Link	pending
0001737287-24-000073.txt	Edgar Link	pending
0001737287-24-000073-xbrl.zip	Edgar Link	pending
allo-20240930.htm	Edgar Link	pending
allo-20240930.xsd	Edgar Link	pending
allo-20240930xex311.htm	Edgar Link	pending
allo-20240930xex312.htm	Edgar Link	pending
allo-20240930xex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
allo-20240930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
allo-20240930_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
allo-20240930_def.xml	Edgar Link	unprocessable
allo-20240930_pre.xml	Edgar Link	unprocessable
allo-20240930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2024 Q4 Form 10-Q Financial Statement

#000173728724000073 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2024 Q4 Form 10-Q Financial Statement

#000173728724000073 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo